In the News: ivWatch Drives Diversity on WAVY TV 10

ivWatch on WAVY TV to Discuss Business Diversity

An interview with Gary Warren, president and CEO of ivWatch, and Andy Fox of WAVY TV 10, highlighted the biotech company as an example of a business driving diversity in the Hampton Roads region of Virginia. The segment features the ivWatch Model 400 and how the company is working to solve a major medical problem while creating jobs. Read the article and view the segment here.

myIV.com Encourages Patients to Take Advocate Pledge

Website for IV therapy information shares new resources and patient stories to help patients #BeYourOwnIVAdvocate

Hampton, Va. – April 25, 2018 – This month, patients were asked to take a pledge to be their own advocate by sharing their intravenous (IV) therapy stories to help others learn more about the procedure. The #BeYourOwnIVAdvocate campaign is hosted on myIV.com, a resource that provides answers to questions about IVs – from the most basic to complex. Sponsored by ivWatch, myIV.com is the first online patient resource of its kind providing visitors simplified information about IVs to foster an informed community of current and future patients.

Nearly 80 percent of all hospital patients receive an IV1, and with more than 150 million placed each year in the U.S., it is one of the most common invasive medical procedures performed. Close to 50 percent of IVs fail due to complications, such as an infiltration, when the fluid or medication intended for the vein leaks into the surrounding tissue. Every failure of an IV results in a drug delivery error and carries the potential for reduced drug effectiveness and physical harm. The myIV.com types of IV failure video educates patients on the symptoms to look out for of the most common complications, like infiltration and phlebitis.

The #BeYourOwnIVAdvocate campaign is focused on empowering patients and family caregivers with knowledge of what to know before a hospital visit. The IV 101: The Basics guide includes:

  • Why patients need IVs
  • How IVs are used
  • The different types of IVs
  • IV Risks

Barby Ingle shared a horrifying experience in a recent video interview about waking up in the middle of surgery due to an infiltration of her anesthesia medication. The WEGO Health Patient Leader stated the importance of getting informed ahead of a hospital visit, “Get the information that you need now, plant the seeds in your brain ahead of time so when you are in that emergency situation and you need help, you can remember back to what you learned on [myIV.com].”

To #BeYourOwnIVAdvocate and, take the pledge at myiv.com/be-your-own-iv-advocate/.

1. Zhang, L., Cao, S., Marsh, N., Ray-Barruel, G., Flynn, J., Larsen, E. and Rickard, C.M. (2016) Infection risks associated with peripheral vascular catheters. Journal of Infection Prevention. 17(5), p.207-213. doi: 10.1177/1757177416655472

About myIV.com
myIV.com is an online patient resource portal dedicated to empowering patients with information on all things IV, simplified. As the first website of its kind focused on IVs and IV therapy, myIV.com fills the gap in patient education and makes IVs easier to understand. myIV.com is sponsored by ivWatch. Help raise #myIVawareness on Twitter, Facebook, Instagram, LinkedIn and Pinterest. For more information, visit www.myIV.com.

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Office (757) 224-2606, Mobile (757) 660-4949

757 Angels and ivWatch Reach Entrepreneurs at Tom Tom Fest

Local business leaders invited to speak at 7th Annual Tom Tom Founders Festival

CHARLOTTESVILLE, Va., April 16, 2018 – 757 Angels and ivWatch recently collaborated during an entrepreneurship session at Tom Tom Founders Festival, a week-long celebration of innovators, visionaries and artists who shape small cities. Part pitch competition, part case study – the organizations co-presented and provided insight into building and growing successful companies and how to foster the next generation of innovators in tech industries.

The session “An Empirical View of the Art and Science of Entrepreneurship and Investment,” was hosted by representatives from the Center for Innovative Technology’s (CIT) GAP Fund on Thursday, April 12. The Hampton Roads entrepreneur community was represented by Monique Adams, executive director of 757 Angels, a group whose membership consists of business and community leaders and Gary Warren, president and CEO of ivWatch, a medical device manufacturer and biosensor technology company. Both shared perspectives from investor and business leader sides of the table.

When asked by session panel member Jayson Rieger, a principle of the PBM Capital Group, about 757 Angels satisfaction with their investment in ivWatch, Adams responded, “ivWatch had incredible momentum early on, and they’ve sustained their competitive advantage. We are extremely pleased with our relationship.”

Virginia Secretary of Commerce and Trade, Esther Lee, opened the event with an announcement of the Virginia Founders Fund, a new seed-stage fund that increases access to venture capital in Virginia. In her comments, she emphasized the ability for software, hardware, life science, cleantech, and technology-enabled services companies to generate economic returns for the Commonwealth.

During his time on stage, Warren touched on the growth and scaling of ivWatch. “Each year we put together an update of the business plan, and we’ve been successful in the execution of our goals. A focus this year is bringing more manufacturing in-house to control quality, cost and bring more high-tech jobs to the area.”

The event brought together regional angel investor and funding groups, including 757 Angels, CIT Gap Fund, Charlottesville Angel Network, and The Launch Place, who each brought one of their most exceptional startups or emerging growth companies they’ve supported. The event focused on the dynamics between the groups and how individual successes support the statewide initiatives outlined by Secretary Lee.

To learn more about ivWatch, visit www.ivWatch.com. To learn more about 757 Angels, visit www.757angelsgroup.com.

About 757 Angels:
757 Angels is a select network of over 100 business and community leaders in the Hampton Roads region, who provide investment capital, strategic advice and mentoring to selected startup and early-stage companies to help them achieve market leadership. 757 Angels seeks dealflow from the Commonwealth of Virginia.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLChttps://www.ivwatch.com/

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

ivWatch Announces Relocation Commitment to Accommodate Growth


Tech Center Research Park welcomes medical device company as anchor tenant

NEWPORT NEWS, Va., March 6, 2018 – ivWatch, the only provider of medical devices for the early detection of intravenous (IV) infiltrations and extravasations, announced today that it is moving forward with plans to relocate from their Hampton and Williamsburg facilities to anchor Newport News Tech Center Research Park‘s Building One. The move will increase operational efficiency by combining all departments, including manufacturing and research and development, under one roof.

“We are experiencing continued growth year after year in staff size, sales and manufacturing operations,” said Gary Warren, president and CEO of ivWatch. “The decision to move to the Research Park supports the execution of our business and recruiting plans. Within the next four years, we plan to add 150 new employees to support our international market-entry and expanding our sales activity in the U.S. through two leading healthcare group purchasing organization(GPO) contracts.”

The company has made substantial progress in developing, designing and commercializing a pioneering non-invasive biosensor technology. Terumo Corporation, one of the world’s leading medical device manufacturers and distributors, was recently named the exclusive distributor for ivWatch in Japan. Additionally, through “Breakthrough” and “Innovative” technology group purchasing contract awards from Premier and Vizient, the ivWatch Model 400 is more accessible to thousands of hospitals and healthcare systems across the U.S.

The Newport News Tech Center will be home to more than one million square feet of space across 11 planned buildings, punctuated by restaurants, shops, fitness clubs, biking trails and gathering spots. With a highly-skilled workforce, the addition of ivWatch to the Research Park will help foster and fuel the technology sector in the Hampton Roads area.

The new headquarter building is part of ivWatch’s investment in supporting their growing operations and customer base as well as the community.

“The best companies are those with access to research, influence and partners with resources you don’t have yet. As a young company in the medical device market, it’s essential to develop and pursue those types of resources to build a company in this tightly regulated industry,” said Warren. “We are proud of the success we’ve achieved, and this workplace will allow us to provide access to others by sharing our journey of how we turned research and data into a solution-based application used in leading hospitals across the country.”

Master building plans include prominent ivWatch signage on the exterior of the building, with ivWatch occupying more than 25,500 sq. ft. including manufacturing, warehouse space on the first floor, and state-of-the-art office space on the first and third floors. The company will keep their open floor plan concept which they’ve found facilitates interdepartmental collaboration. The building will include space for other tenants, co-working spaces and a business accelerator program.

The construction of the building is underway, with a target move-in date of late 2018.

To learn more about ivWatch, visit www.ivWatch.com. To learn more about Tech Center Research Park, visit innovateattechcenterva.com.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLChttps://www.ivWatch.com/

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

ivWatch Intellectual Property Grows with Three International Patents

Latest patent grants cover core product technologies

HAMPTON, Va., February 8, 2018 – ivWatch, the only provider of continuous monitoring devices for the early detection of peripheral intravenous (PIV) infiltrations and extravasations, recently had three patent applications granted by the Japanese and Australian Patent Offices expanding the company’s intellectual property portfolio.

“Today’s healthcare marketplace is growing increasingly competitive with the introduction of new devices and technologies, so we must continue to build on our successes in this space by protecting our innovations,” said Gary Warren, president and CEO of ivWatch. “Our philosophy regarding intellectual property is to aggressively protect our proprietary technology to expand our product portfolio and develop licensing opportunities with strategic partners.”

Granted Japanese Patent Application No. 2015-553708 is for a core technology regarding the geometry of ivWatch sensor heads – for both the fiber optic and electronic systems – which has secured ivWatch’s position as a first, and only, technology of its kind in the market. Optimal light angles and distances of the various sensor parts allow the technology to detect infiltrations with high sensitivity to aid healthcare providers in an early diagnosis of these most serious events during intravenous (IV) therapy.

Granted Japanese Patent Application No. 2015-510267 is for a second core technology regarding how an ivWatch sensor head adheres to and is secured on a patient’s skin. These appliances, more commonly known as receptacles, may be independent of the dressings that cover infusion sites during IV therapy or may be integrated with those dressings. The granting of these applications comes just months after ivWatch entered into a licensing and distribution agreement with Terumo Corporation helping to advance patient safety in Japan and on a global scale.

Australian Patent No. 2013316021 is directed to a third core technology for mitigating the effects of tissue blood volume changes. The Australian patent corresponds to U.S. Patent No. 9,326,686, for solving motion issues related to continuous PIV therapy monitoring. The patent is directly related to the ability of the ivWatch Model 400 to reduce the number of “false” notifications helping combat an epidemic of clinicians becoming desensitized to alarms, many of which are false or clinically irrelevant.

These new grants are in addition to the two patents already in ivWatch’s intellectual property portfolio, which also includes numerous utility patent applications. This portfolio gives ivWatch the right to prevent others from making, using or selling our products in the U.S. and major international markets.

There is a rapid demand for breakthrough technology as more healthcare facilities focus on value-based care to lower costs and improve patient safety and satisfaction. IV infiltration and extravasation is a major problem as it can lead to serious medical complications and even amputation. The ivWatch Model 400 continuously monitors a patient’s PIV for evidence of infiltrations and extravasations, which occur when medication or fluid leaks into the surrounding tissue. Early detection of those failures via ivWatch biosensor technology helps to minimize injuries associated with this common complication of IV therapy.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLChttps://www.ivWatch.com/

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

ivWatch Awarded Breakthrough Technology Agreement with Premier

HAMPTON, Va.., February 6, 2018 – ivWatch, LLC has been awarded a group purchasing agreement as a Breakthrough Technology with Premier. Effective Feb.1, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the ivWatch Model 400, a continuous monitoring device for the early detection of peripheral IV (PIV) infiltrations.

“We are thrilled to be recognized by Premier as a Breakthrough Technology which accelerates the standard GPO process and enables us to educate more organizations about our technology offering a new standard of care for PIVs,” said Scott Hensley, vice president of sales and business development at ivWatch. “This recognition is a testament to the need for a technology solution in hospitals for continuous IV monitoring for early detection of IV infiltrations and extravasations.”

This relationship enables Premier members to implement continuous monitoring of a patient’s PIV for evidence of infiltrations to improve patient outcomes. Intravenous therapy is a routine part of treatment for nearly 80 percent of patients in the U.S., yet more than 20 percent of these IVs may fail due to infiltration, risking both a serious drug delivery error and tissue damage. The ivWatch sensor technology is a solution to aid the clinician in early detection of this most serious event.

Premier is a leading healthcare improvement company, uniting an alliance of approximately 3,900 U.S. hospitals and 150,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLChttps://www.ivwatch.com/

ivWatch Logo White

Download Our Whitepaper

Thank you for requesting more information about the ivWatch Clinical Studies. The ivWatch Model 400 is the only continuous monitoring device for the early detection of IV infiltration and extravasation events.

[fc id='6'][/fc]

You have Successfully Subscribed!

Pin It on Pinterest